[go: up one dir, main page]

US20110124682A1 - Pharmaceutical composition comprising rebamipide - Google Patents

Pharmaceutical composition comprising rebamipide Download PDF

Info

Publication number
US20110124682A1
US20110124682A1 US12/999,967 US99996709A US2011124682A1 US 20110124682 A1 US20110124682 A1 US 20110124682A1 US 99996709 A US99996709 A US 99996709A US 2011124682 A1 US2011124682 A1 US 2011124682A1
Authority
US
United States
Prior art keywords
pharmaceutical composition
rebamipide
acid
yellowish
glycerin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/999,967
Inventor
Shun-ichiro Sumida
Shinichi Ishikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Assigned to OTSUKA PHARMACEUTICAL CO., LTD. reassignment OTSUKA PHARMACEUTICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SUMIDA, SHUN-ICHIRO, ISHIKAWA, SHINICHI
Publication of US20110124682A1 publication Critical patent/US20110124682A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Definitions

  • the present invention relates to a pharmaceutical composition.
  • Rebamipide [chemical name: (+)-2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid] is known as a useful antiulcer drug.
  • rebamipide has an increasing action of goblet cell density in eye, an increasing action of mucus in eye, and an increasing action of lacrimal fluid, and has been already known as an agent for treating dry eye, i.e. dry eye syndrome (WO 97/013515).
  • Rebamipide is soluble in an alkaline aqueous solution, but the solubility of rebamipide in a neutral solution is quite low. On the other hand, a high-pH eye drop is not suitable for a patient suffering from an injury in keratoconjunctiva such as dry eye. Additionally, even in case of an alkaline solution containing rebamipide, a crystal of rebamipide may be occasionally deposited and hence it is thought that the development of an aqueous ophthalmic product of rebamipide is difficult.
  • WO 97/013515 discloses a neutral aqueous suspension containing rebamipide.
  • the suspension may form a precipitate layer when standing for a long period. Therefore, the suspension needs to be shaken well in order to be re-dispersed.
  • such suspension product may be thought to have some demerits, for example suffering from blurred vision and making some white spots on the cloths when spilling the suspension, because the suspension product is a white ophthalmic suspension.
  • WO 2008/050896 discloses an aqueous suspension containing rebamipide wherein rebamipide is stably dispersed in a state of fine particles and additionally the fine particles are not re-agglutinated.
  • the aqueous suspension containing rebamipide in WO 2008/050896 is improved about suspensibility compared with the production of the above-mentioned WO 97/013515.
  • the aqueous suspension containing rebamipide in WO 2008/050896 is also necessary to be shaken well in order to be re-dispersed, since the suspension in WO 2008/050896 is a white ophthalmic suspension wherein rebamipide is not completely dissolved and it is impossible to avoid forming a precipitate layer of rebamipide when standing for a long period. Furthermore, the demerits such as suffering from blurred vision and making some white spots on the cloths when spilling the suspension, have not been solved in WO 2008/050896 yet.
  • WO 2006/052018 discloses an aqueous suspension containing crystalline rebamipide which comprises a mixture of at least one of the compounds selected from water-soluble polymers and surfactants, an aqueous acidic solution, and an aqueous solution containing a water-soluble salt of rebamipide, which is not necessary to be re-dispersed, has an enough transparency, and is a neutral suspension not to injure the keratoconjunctiva of a patient suffering from dry eye.
  • the aqueous suspension containing crystalline rebamipide in WO 2006/052018 has a problem of high production cost, since some expensive equipments such as a high-pressure homogenizer, a colloidmill, and a sonicator are required in the process, and the manufacturing process is troublesome, complicated, and long-term.
  • a preservative-free ophthalmic agent In general, to a conventional ophthalmic agent is added a preservative in order to prevent microbial contamination.
  • a preservative-free ophthalmic agent is required because a preservative is harmful to the patient.
  • Vessels known for a preservative-free ophthalmic agent include a disposable plastic single-dose unit and a multi-use vessel equipped with a filter which can capture bacteria around the drip opening.
  • the aqueous suspensions in the above-mentioned WO 2008/050896 and WO 2006/052018 are hard to pass through the filter, thus it is impossible to use the multi-use vessel, and it is necessary to use a comparatively-expensive single-dose unit.
  • An object of the present invention is to provide a pharmaceutical composition containing rebamipide, which is unnecessary to be re-dispersed, has an enough transparency, and exhibits neutral to weakly acidic pH not to injure the keratoconjunctiva of a patient suffering from dry eye.
  • the pharmaceutical composition is an ophthalmic composition.
  • an object of the present invention is to provide a pharmaceutical composition which can be prepared at low cost without using expensive equipments.
  • the present inventors have extensively studied to reach the above object and then have found that a pharmaceutical composition comprising (1) rebamipide, (2) an amino sugar, and (3) an buffer agent, which has no cation, has a good re-dispersibility and an enhanced transparency. In addition, the present inventors have also found that the present pharmaceutical composition has an antimicrobial effectiveness. Based upon the new findings, the present invention has been completed.
  • the present invention provides pharmaceutical compositions and use thereof, as shown in the following [1] to [8].
  • a pharmaceutical composition comprising (1) rebamipide, (2) an amino sugar, and (3) an buffer agent, which has no inorganic cation.
  • amino sugar is at least one selected from the group consisting of D-glucosamine and meglumine.
  • composition of [5] wherein the solubilizing agent is at least one selected from the group consisting of polyvinylpyrrolidone and macrogol.
  • the pharmaceutical composition of the present invention is a composition comprising (1) rebamipide, (2) an amino sugar and (3) an buffer agent, which comprises no inorganic cation.
  • the pharmaceutical composition is preferably formulated as an aqueous liquid preparation, and more preferably used as an ophthalmic pharmaceutical composition.
  • the concentration of rebamipide in the pharmaceutical composition of the invention is about 0.1 (W/V) to about 5% (W/V), preferably about 0.5% (W/V) to about 3% (W/V), more preferably about 1% (W/V) to about 2% (W/V).
  • 1% (W/V) herein used means a concentration of 1 g per 100 mL.
  • the cation herein used refers to an inorganic cation, and includes, for example, a monovalent alkaline metal cation such as lithium ion, sodium ion, potassium ion, and cesium ion; and bivalent alkaline earth metal cation such as magnesium ion and calcium ion.
  • a monovalent alkaline metal cation such as lithium ion, sodium ion, potassium ion, and cesium ion
  • bivalent alkaline earth metal cation such as magnesium ion and calcium ion.
  • a pharmaceutical composition has no inorganic cation” herein used means “a pharmaceutical composition does not virtually have an inorganic cation”. In more detail, it means that the amount of an inorganic cation in the pharmaceutical composition is less than 15 mEq, preferably less than 1.5 mEq, more preferably less than 0.3 mEq.
  • the amino sugar herein used includes, for example, meglumine (i.e. N-methyl-D-glucamine), D-glucosamine, D-galactosamine, D-mannosamine, mycosamine, kanosamine, neosamine C, N-methyl-L-glucosamine, mycaminose, muramic acid, and streptamine.
  • meglumine i.e. N-methyl-D-glucamine
  • D-glucosamine i.e. N-methyl-D-glucamine
  • D-glucosamine D-galactosamine
  • D-mannosamine D-mannosamine
  • mycosamine kanosamine
  • neosamine C N-methyl-L-glucosamine
  • mycaminose muramic acid
  • streptamine streptamine
  • the preferable amino sugars are meglumine, D-glucosamine, D-galactosamine, D-mannosamine, mycosamine, kanosamine, neosamine C, N-methyl-L-glucosamine, mycaminose, muramic acid, and streptamine; especially meglumine and D-glucosamine are more preferable.
  • the above amino sugars may be used as a single ingredient or a combination consisting of two or more ingredients.
  • the concentration of the amino sugar in the pharmaceutical composition of the invention is, for example, about 0.1% (W/V) to about 15% (W/V), preferably about 0.5% (W/V) to about 10% (W/V), more preferably about 1% (W/V) to about 8% (W/V).
  • the buffer agent herein used includes, for example, an acid which is not in cation form, such as boric acid, phosphoric acid, an amino acid, and an organic acid; preferably boric acid and phosphoric acid are used.
  • the above buffer agents may be used as a single ingredient or a combination consisting of two or more ingredients.
  • the concentration of the buffer agent in the pharmaceutical composition of the invention is, for example, about 0.01% (W/V) to about 4% (W/V), preferably about 0.03% (W/V) to about 3% (W/V), more preferably about 0.05% (W/V) to about 2% (W/V).
  • the pharmaceutical composition of the invention may optionally contain a pH adjuster.
  • the pH adjuster includes, for example, a conventional acid which is in cation-free form, such as hydrochloric acid, lactic acid, acetic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid, and citric acid; preferably hydrochloric acid and citric acid are used.
  • the pH adjusters may be used as a single ingredient or a combination consisting of two or more ingredients.
  • the pharmaceutical composition of the invention may optionally contain an isotonic agent in order to make the pharmaceutical composition isotonic to an aqueous tear.
  • the isotonic agent is preferably a cation-free isotonic agent, which includes a conventional agent for ophthalmic solution such as mannitol, glycerin, polypropylene glycol, polyethylene glycol, maltose, sucrose, sorbitol, and glucose, more preferably a cation-free glycerin and sucrose are used.
  • the isotonic agents may be used as a single ingredient or a combination consisting of two or more ingredients.
  • the pharmaceutical composition of the invention may optionally contain a solubilizing agent.
  • the solubilizing agent includes, for example, a cation-free solubilizing agent.
  • the cation-free solubilizing agent includes, for example, a polymer such as polyvinyl-pyrrolidone, macrogol (polyethylene glycol), polyvinyl alcohol, and hydroxypropylmethylcellulose; a surfactant such as polysorbate, polyoxyethylene hydrogenated castor oil, and polyoxyethylene-polyoxypropylene; a polyhydric alcohol such as polypropylene glycol; an organic acid such as benzoic acid and sorbic acid; an amino acid such as alginic acid, histidine, glycine, and lysine; and a xanthine derivative such as caffeine.
  • the preferable solubilizing agent is polyvinylpyrrolidone, macrogol, polyvinyl alcohol, benzoic acid, sorbic acid, and alginic acid; especially, more preferable solubilizing agent is polyvinylpyrrolidone and macrogol.
  • the solubilizing agents may be used as a single ingredient or a combination consisting of two or more ingredients.
  • the molecular weight of polyvinylpyrrolidone herein used is preferably not more than 200,000, more preferably not more than 40,000.
  • the preferable polyvinyl-pyrrolidone includes, not limited thereto, polyvinyl-pyrrolidone (PVP, BASF, Grade: Kollidon® 25): PVP (K-25), and polyvinylpyrrolidone (PVP, BASF, Grade: Kollidon® 17PF): PVP (K-17PF).
  • the concentration ratio of rebamipide and polyvinylpyrrolidone is preferably 20:1-1:20, more preferably 4:1-1:6.
  • the molecular weight of macrogol herein used is preferably not more than 50,000, more preferably not more than 10,000.
  • the preferable macrogol includes, not limited thereto, macrogol 1500, macrogol 4000, macrogol 6000, and macrogol 20000.
  • the concentration ratio of rebamipide and macrogol is preferably 20:1-1:20, more preferably 4:1-1:6.
  • the concentration of solubilizing agent is in a range of generally about 0.01 (W/V)-about 15 (W/V) %, preferably about 0.1 (W/V) %-about 10 (W/V) %, and more preferably about 0.5 (W/V) %-about 6 (W/V) %.
  • the pharmaceutical composition of the invention may optionally comprise a conventional preservative such as a quaternary ammonium salt (e.g. benzalkonium chloride, and benzethonium chloride, chlorhexidine gluconate, a paraoxybenzoate (e.g. methyl paraoxybenzoate and propyl paraoxybenzoate), and an alcohol compound (e.g. chlorobutanol and benzyl alcohol); and/or stabilizing agent such as an inorganic-cation-free ascorbic acid and tocopherol.
  • a conventional preservative such as a quaternary ammonium salt (e.g. benzalkonium chloride, and benzethonium chloride, chlorhexidine gluconate, a paraoxybenzoate (e.g. methyl paraoxybenzoate and propyl paraoxybenzoate), and an alcohol compound (e.g. chlorobutanol and benzyl alcohol); and/or stabilizing agent such as an inorganic-
  • the pH is about 3-about 9, preferably about 7-about 9, and the most preferably 7.7-9.
  • the ratio between (1) rebamipide and (2) an amino sugar comprised in the present composition depends on the type of ingredients used herein and the formulation type of the composition.
  • the amount of (1) rebamipide is, but not limited to, for example, in about 0.01-about 10 parts by weight, preferably about 0.05-about 2 parts by weight, more preferably about 0.1-about 1.5 parts by weight, and the most preferably 0.1-1 part by weight, per one part by weight of (2) an amino sugar.
  • a preferable pharmaceutical composition of the present invention is a pharmaceutical composition comprising (1) rebamipide, (2) meglumine and (3) boric acid, which comprises no inorganic cation.
  • a more preferable pharmaceutical composition is a pharmaceutical composition comprising 0.5% (W/V) to 3% (W/V) rebamipide, 0.5% (W/V) to 10% (W/V) meglumine, and 0.03% (W/V) to 3% (W/V) boric acid, which comprises no inorganic cation.
  • An even more preferable pharmaceutical composition is a pharmaceutical composition comprising 1 (W/V) to 2% (W/V) rebamipide, 1 (W/V) to 8% (W/V) meglumine, 0.05% (W/V) to 2% (W/V) boric acid, and a pH adjuster selected from the group consisting of citric acid and hydrochloric acid, which comprises no inorganic cation.
  • the most preferable pharmaceutical composition is the above-mentioned pharmaceutical composition further comprising polyvinylpyrrolidone as a solubilizing agent.
  • concentration of the solubilizing agent is preferably 0.5 (W/V) % to 6 (W/V).
  • the transparency of the present pharmaceutical composition comprising (1) rebamipide, (2) an amino sugar, and (3) an buffer agent can be enhanced by not containing any inorganic cation.
  • the present pharmaceutical composition is unnecessary to be re-dispersed, additionally it can be formulated into an aqueous preparation which has an enough transparency, and exhibits neutral to weakly acidic pH.
  • the present pharmaceutical composition has an antiseptic effect, thus it is expected to exhibit a preservative effect. Therefore, the present aqueous preparation is not necessary to comprise a conventional preservative (e.g. a quaternary ammonium salt such as benzalkonium chloride and benzethonium chloride; a cationic compound such as chlorhexidine gluconate; a paraoxy benzoate such as methyl paraoxybenzoate and propyl paraoxybenzoate; and an alcohol compound such as chlorobutanol and benzyl alcohol).
  • a conventional preservative e.g. a quaternary ammonium salt such as benzalkonium chloride and benzethonium chloride
  • a cationic compound such as chlorhexidine gluconate
  • a paraoxy benzoate such as methyl paraoxybenzoate and propyl paraoxybenzoate
  • an alcohol compound such as chlorobutanol and benzyl alcohol
  • the present pharmaceutical composition is so stable, thus it is not necessary to add hereto any stabilizing agent (e.g. an inorganic-cation-free ascorbic acid and tocopherol).
  • any stabilizing agent e.g. an inorganic-cation-free ascorbic acid and tocopherol.
  • the manufacturing process of the present pharmaceutical composition can be carried out at low cost, not via any troublesome process, without using any special dispersing/suspending device, which is an industrially great merit.
  • the present aqueous ophthalmic product can prevent an undesirable blurred vision of an applied patient, thus it is expected to markedly enhance the compliance of a patient suffering from dry eye, and it enables the use of a multi-use vessel equipped with an aseptic filter around the drip opening which is for a preservative-free ophthalmic agent, because it can be pass through an aseptic filter. Therefore, the present invention will provide a great amount of medicinal contribution.
  • the present pharmaceutical composition has an excellent transparency, thus there is no trouble of making some white spots on the cloths when spilling the composition.
  • the stirring was done with a low-speed propeller stirrer, without a high-speed stirrer such as a homomixer and a homogenizer. Every ingredient was easily dissolved with the low-speed propeller stirrer. Then, the resulting solution was aseptically filtered through a 0.2 ⁇ m filter to provide a pharmaceutical composition.
  • the pharmaceutical composition was a colorless to light-yellowish transparent solution.
  • the stirring was done with a low-speed propeller stirrer, without a high-speed stirrer such as a homomixer and a homogenizer. Every ingredient was easily dissolved with the low-speed propeller stirrer. Then, the resulting solution was aseptically filtered through a 0.2 ⁇ m filter to provide a pharmaceutical composition.
  • the pharmaceutical composition was a colorless to light-yellowish transparent solution.
  • a yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 1, using polyvinylpyrrolidone (K-17) in place of polyvinylpyrrolidone (K-25).
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 2, using polyvinylpyrrolidone (K-17) in place of polyvinylpyrrolidone (K-25).
  • a colorless to light-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 3, using polyvinylpyrrolidone (K-17) in place of polyvinylpyrrolidone (K-25).
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 4, using polyvinylpyrrolidone (K-17) in place of polyvinylpyrrolidone (K-25).
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 5, using polyvinylpyrrolidone (K-17) in place of polyvinylpyrrolidone (K-25).
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 6, using polyvinylpyrrolidone (K-17) in place of polyvinylpyrrolidone (K-25).
  • a colorless to light-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 7, using polyvinylpyrrolidone (K-17) in place of polyvinylpyrrolidone (K-25).
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 8, using polyvinylpyrrolidone (K-17) in place of polyvinylpyrrolidone (K-25).
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 1, using citric acid in place of hydrochloric acid.
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 2, using citric acid in place of hydrochloric acid.
  • a colorless to light-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 3, using citric acid in place of hydrochloric acid.
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 4, using citric acid in place of hydrochloric acid.
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 5, using citric acid in place of hydrochloric acid.
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 6, using citric acid in place of hydrochloric acid.
  • a colorless to light-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 7, using citric acid in place of hydrochloric acid.
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 8, using citric acid in place of hydrochloric acid.
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 1, using sucrose (2.889 g) in place of glycerin (0.722 g).
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 2, using sucrose (4.741 g) in place of glycerin (1.185 g).
  • a colorless to light-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 3, using sucrose (3.185 g) in place of glycerin (0.796 g).
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 4, using sucrose (1.593 g) in place of glycerin (0.398 g).
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 5, using sucrose (3.963 g) in place of glycerin (0.991 g).
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 6, using sucrose (5.556 g) in place of glycerin (1.389 g).
  • a colorless to light-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 7, using sucrose (4.185 g) in place of glycerin (1.046 g).
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 8, using sucrose (2.704 g) in place of glycerin (0.676 g).
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 1, using sucrose (2.889 g) in place of glycerin (0.722 g) and using citric acid in place of hydrochloric acid.
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 5, using sucrose (3.963 g) in place of glycerin (0.991 g) and using citric acid in place of hydrochloric acid.
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 1, using sucrose (2.889 g) in place of glycerin (0.722 g) and using phosphoric acid in place of hydrochloric acid.
  • a light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 5, using sucrose (3.963 g) in place of glycerin (0.991 g) and using phosphoric acid in place of hydrochloric acid.
  • the stirring was done with a low-speed propeller stirrer, without a high-speed stirrer such as a homomixer and a homogenizer. Every ingredient was easily dissolved with the low-speed propeller stirrer. Then, the resulting solution was aseptically filtered through a 0.2 ⁇ m filter to provide a pharmaceutical composition.
  • the pharmaceutical composition was a colorless transparent solution.
  • the stirring was done with a low-speed propeller stirrer, without a high-speed stirrer such as a homomixer and a homogenizer. Every ingredient was easily dissolved with the low-speed propeller stirrer. Then, the resulting solution was aseptically filtered through a 0.2 ⁇ m filter to provide a pharmaceutical composition.
  • the pharmaceutical composition was a colorless transparent solution.
  • the stirring was done with a low-speed propeller stirrer, without a high-speed stirrer such as a homomixer and a homogenizer. Every ingredient was easily dissolved with the low-speed propeller stirrer. Then, the resulting solution was aseptically filtered through a 0.2 ⁇ m filter to provide a pharmaceutical composition.
  • the pharmaceutical composition was a colorless transparent solution.
  • the stirring was done with a low-speed propeller stirrer, without a high-speed stirrer such as a homomixer and a homogenizer. Every ingredient was easily dissolved with the low-speed propeller stirrer. Then, the resulting solution was aseptically filtered through a 0.2 ⁇ m filter to provide a pharmaceutical composition.
  • the pharmaceutical composition was a colorless transparent solution.
  • a colorless transparent pharmaceutical composition was prepared in a similar manner to Example 37, using citric acid in place of hydrochloric acid.
  • a colorless transparent pharmaceutical composition was prepared in a similar manner to Example 39, using citric acid in place of hydrochloric acid.
  • a colorless transparent pharmaceutical composition was prepared in a similar manner to Example 37, using sucrose (3.444 g) in place of glycerin (0.861 g).
  • a colorless transparent pharmaceutical composition was prepared in a similar manner to Example 39, using sucrose (5.148 g) in place of glycerin (1.287 g).
  • a colorless transparent pharmaceutical composition was prepared in a similar manner to Example 37, using sucrose (3.444 g) in place of glycerin (0.861 g) and using citric acid in place of hydrochloric acid.
  • a colorless transparent pharmaceutical composition was prepared in a similar manner to Example 39, using sucrose (5.148 g) in place of glycerin (1.287 g) and using citric acid in place of hydrochloric acid.
  • a colorless transparent pharmaceutical composition was prepared in a similar manner to Example 37, using sucrose (3.444 g) in place of glycerin (0.861 g) and using phosphoric acid in place of hydrochloric acid.
  • a colorless transparent pharmaceutical composition was prepared in a similar manner to Example 39, using sucrose (5.148 g) in place of glycerin (1.287 g) and using phosphoric acid in place of hydrochloric acid.
  • compositions of Examples 4952 and Comparative examples 1-5 shown in the following Table 1 were prepared in the same manner as Example 1, using each ingredient and each amount thereof described in Table 1, each of which was a transparent pharmaceutical composition having a pH range of 7-9.
  • the compositions were stored in a refrigerator for 4 weeks and then each aspect of the compositions was observed and recorded.
  • a precipitate or gel was formed in the pharmaceutical compositions of Comparative examples 1-5 which contained an inorganic cation.
  • a precipitate or gel was not formed at all.
  • Example Comparative Comparative Comparative Comparative Example Comparative Example 49 example 1 example 2 example 3 example 4 50 example 5 51 52 Rebamipide (g) 2.02 2.02 2.02 2.02 2.02 2.02 2.02 Meglumine (g) 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 PVP K25 (g) 4 4 4 4 4 4 — — Macrogol (g) — — — — — — — 3 Boric acid (g) 1 — — — — 1 1 1 1 Borax 1) (g) — 1.9 — — — — — — — — Phosphate Na (g) — — 1 — — — — — — — Citrate Na (g) — — — 1 — — — — — — Carbonate Na (g) — — — — — — 1 — — — — Citric anhydride q.s.
  • Example 1 In order to confirm the good transparency and the good permeability of the present pharmaceutical composition, Example 1, Example 37, Comparative example 6 according to WO 2008/050896, and Comparative example 7 according to WO 2006/052018 were prepared. Shortly after each composition was prepared, each the aspect, the optical transparency at 640 nm, and the filtration performance over a 0.2 ⁇ m membrane filter were observed and recorded. After the compositions were stood at room temperature for four weeks, each the aspect was observed and recorded.
  • Example 2 The results are shown in Table 2.
  • the optical transparency thereof was not interrupted, the filtration performance thereof was good, and the aspect thereof was not changed even after 4 weeks.
  • the pharmaceutical composition of Comparative example 6 was milky white, i.e. not transparent, and it was hard to be filtered.
  • the pharmaceutical composition of Comparative example 7 was white, and it could not be filtered since the filter was blocked with its crystal.
  • the pharmaceutical composition of Comparative example 7 which was stood for 4 weeks had to be vigorously shaken for re-dispersion since the crystal was deposited.
  • the above sodium hydroxide solution containing rebamipide was gradually poured under sonication to deposit a crystal of rebamipide. After the crystal was deposited, the stirring speed was picked up to 3000 rpm, and the mixture was stirred for additional 20 minutes. After completing the deposition, the pH of the mixture was adjusted to 6-6.5 with 5 N sodium hydroxide, and the total volume thereof was adjusted to 1 liter with purified water to provide the desired aqueous suspension containing crystalline rebamipide.
  • Example 37 example 6 example 7 Shortly after Aspect transparent transparent milky white white preparation transparent Optical 100.0 100.0 44.5 0.0 transparency at 640 nm (%) Filtration very good very good a little blocked with performance bad crystal over a 0.2 ⁇ m membrane filter After Aspect not changed not changed not changed Crystal was 4 weeks deposited. Re-dispersed by vigorously shaking.
  • Examples 53-58 were prepared in a similar manner to Example 1 using ingredients listed in Table 3.
  • compositions for antimicrobial effectiveness test Example Example Example Example Example 53 54 55 56 57 58 Rebamipide 2 g 2 g 2 g 2 g 2 g 2 g PVP (K25) — — 3 g 3 g — — PVP (K17) — — — — — 3 g 3 g Boric acid 1.5 g 2 g 1.5 g 2 g 1.5 g 1.2 g Meglumine 6.2 g 7.9 g 5.9 g 7.4 g 5.7 g 4.8 g Glycerin 0.972 g 0.616 g 0.844 g 0.5 g 0.819 g 1.05 g 10% HCl q.s. q.s. q.s.
  • PVP polyvinylpyrrolidone
  • each inoculum was aseptically added to Examples 53-58 at 10 5 -10 6 cfu/mL, and each composition was uniformly mixed to provide each test sample. These samples were stored at 20-25° C. protected from light. On 0, 14 and 28 days, each 1 mL was sampled from each test sample, and measured as to its viable cell count.
  • the measure of viable cell count of yeast and molds was carried out as follows. Each of the sample solutions was diluted in a tenfold dilutions with SCDLP medium. 1 mL of each grade of the dilutions was plated and 15-20 mL of SCDLP agar medium was added thereto. After cultivating the medium at 30-35° C. for 5 days, the measure of viable cell count was carried out. A plate wherein the viable cell count was not more than 300 was selected and the number of the count was recorded.
  • the measure of viable cell count of fungi was carried out as follows. Each of the sample solutions was diluted in a tenfold dilutions with GPLP medium. 1 mL of each grade of the dilutions was plated and 15-20 mL of GPLP agar medium was added thereto. After cultivating the medium at 20-25° C. for 5 days, the measure of viable cell count was carried out. A plate wherein the viable cell count was not more than 100 was selected and the number of the count was recorded.
  • the viable cell count of each sample solution was provided by multiplying the recorded number by its dilution rate, and additionally the percentage of the viable cell count per the initial viable cell count was calculated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

An object of the present invention is to provide a pharmaceutical composition containing rebamipide, which is unnecessary to be re-dispersed, has an enough transparency, and exhibits neutral to weakly acidic pH not to injure the keratoconjunctiva of a patient suffering from dry eye. The present pharmaceutical composition comprises (1) rebamipide, (2) an amino sugar, and (3) an buffer agent, which has no inorganic cation.

Description

    TECHNICAL FIELD
  • The present invention relates to a pharmaceutical composition.
    • BACKGROUND ART
  • Rebamipide [chemical name: (+)-2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid] is known as a useful antiulcer drug.
  • In addition, rebamipide has an increasing action of goblet cell density in eye, an increasing action of mucus in eye, and an increasing action of lacrimal fluid, and has been already known as an agent for treating dry eye, i.e. dry eye syndrome (WO 97/013515).
  • Rebamipide is soluble in an alkaline aqueous solution, but the solubility of rebamipide in a neutral solution is quite low. On the other hand, a high-pH eye drop is not suitable for a patient suffering from an injury in keratoconjunctiva such as dry eye. Additionally, even in case of an alkaline solution containing rebamipide, a crystal of rebamipide may be occasionally deposited and hence it is thought that the development of an aqueous ophthalmic product of rebamipide is difficult.
  • WO 97/013515 discloses a neutral aqueous suspension containing rebamipide. However, the suspension may form a precipitate layer when standing for a long period. Therefore, the suspension needs to be shaken well in order to be re-dispersed. In addition, such suspension product may be thought to have some demerits, for example suffering from blurred vision and making some white spots on the cloths when spilling the suspension, because the suspension product is a white ophthalmic suspension.
  • WO 2008/050896 discloses an aqueous suspension containing rebamipide wherein rebamipide is stably dispersed in a state of fine particles and additionally the fine particles are not re-agglutinated. The aqueous suspension containing rebamipide in WO 2008/050896 is improved about suspensibility compared with the production of the above-mentioned WO 97/013515. However, the aqueous suspension containing rebamipide in WO 2008/050896 is also necessary to be shaken well in order to be re-dispersed, since the suspension in WO 2008/050896 is a white ophthalmic suspension wherein rebamipide is not completely dissolved and it is impossible to avoid forming a precipitate layer of rebamipide when standing for a long period. Furthermore, the demerits such as suffering from blurred vision and making some white spots on the cloths when spilling the suspension, have not been solved in WO 2008/050896 yet.
  • WO 2006/052018 discloses an aqueous suspension containing crystalline rebamipide which comprises a mixture of at least one of the compounds selected from water-soluble polymers and surfactants, an aqueous acidic solution, and an aqueous solution containing a water-soluble salt of rebamipide, which is not necessary to be re-dispersed, has an enough transparency, and is a neutral suspension not to injure the keratoconjunctiva of a patient suffering from dry eye.
  • However, the aqueous suspension containing crystalline rebamipide in WO 2006/052018 has a problem of high production cost, since some expensive equipments such as a high-pressure homogenizer, a colloidmill, and a sonicator are required in the process, and the manufacturing process is troublesome, complicated, and long-term.
  • In general, to a conventional ophthalmic agent is added a preservative in order to prevent microbial contamination. For a patient suffering from corneal disorder such as dry eye, however, a preservative-free ophthalmic agent is required because a preservative is harmful to the patient. Vessels known for a preservative-free ophthalmic agent include a disposable plastic single-dose unit and a multi-use vessel equipped with a filter which can capture bacteria around the drip opening. However, the aqueous suspensions in the above-mentioned WO 2008/050896 and WO 2006/052018 are hard to pass through the filter, thus it is impossible to use the multi-use vessel, and it is necessary to use a comparatively-expensive single-dose unit.
  • Therefore, it has been desired to develop a pharmaceutical composition containing rebamipide, which is unnecessary to be re-dispersed, has an enough transparency, and exhibits neutral to weakly acidic pH not to injure the keratoconjunctiva of a patient suffering from dry eye, and a process for preparing such pharmaceutical composition at low cost without using expensive equipments.
    • DISCLOSURE OF INVENTION Problem to be Solved by the Invention
  • An object of the present invention is to provide a pharmaceutical composition containing rebamipide, which is unnecessary to be re-dispersed, has an enough transparency, and exhibits neutral to weakly acidic pH not to injure the keratoconjunctiva of a patient suffering from dry eye. In detail, the pharmaceutical composition is an ophthalmic composition.
  • In addition, an object of the present invention is to provide a pharmaceutical composition which can be prepared at low cost without using expensive equipments.
    • Means to Solve the Problem
  • The present inventors have extensively studied to reach the above object and then have found that a pharmaceutical composition comprising (1) rebamipide, (2) an amino sugar, and (3) an buffer agent, which has no cation, has a good re-dispersibility and an enhanced transparency. In addition, the present inventors have also found that the present pharmaceutical composition has an antimicrobial effectiveness. Based upon the new findings, the present invention has been completed.
  • The present invention provides pharmaceutical compositions and use thereof, as shown in the following [1] to [8].
  • [1] A pharmaceutical composition comprising (1) rebamipide, (2) an amino sugar, and (3) an buffer agent, which has no inorganic cation.
  • [2] The pharmaceutical composition of [1] wherein the amino sugar is at least one selected from the group consisting of D-glucosamine and meglumine.
  • [3] The pharmaceutical composition of [1] or [2] wherein the buffer agent is at least one selected from the group consisting of boric acid, phosphoric acid and an amino acid.
  • [4] The pharmaceutical composition of any one of [1] to [3], further comprising a pH adjuster.
  • [5] The pharmaceutical composition of any one of [1] to [4], further comprising a solubilizing agent.
  • [6] The pharmaceutical composition of [5] wherein the solubilizing agent is at least one selected from the group consisting of polyvinylpyrrolidone and macrogol.
  • [7] The pharmaceutical composition of any one of [1] to [6] wherein the pharmaceutical composition is an ophthalmic pharmaceutical composition.
  • [8] Use of the pharmaceutical composition of any one of [1] to [7] for treating dry eye by topically administering to eyes.
  • The pharmaceutical composition of the present invention is a composition comprising (1) rebamipide, (2) an amino sugar and (3) an buffer agent, which comprises no inorganic cation.
  • The pharmaceutical composition is preferably formulated as an aqueous liquid preparation, and more preferably used as an ophthalmic pharmaceutical composition.
  • The concentration of rebamipide in the pharmaceutical composition of the invention is about 0.1 (W/V) to about 5% (W/V), preferably about 0.5% (W/V) to about 3% (W/V), more preferably about 1% (W/V) to about 2% (W/V). For example, “1% (W/V)” herein used means a concentration of 1 g per 100 mL.
  • The cation herein used refers to an inorganic cation, and includes, for example, a monovalent alkaline metal cation such as lithium ion, sodium ion, potassium ion, and cesium ion; and bivalent alkaline earth metal cation such as magnesium ion and calcium ion.
  • The term “a pharmaceutical composition has no inorganic cation” herein used means “a pharmaceutical composition does not virtually have an inorganic cation”. In more detail, it means that the amount of an inorganic cation in the pharmaceutical composition is less than 15 mEq, preferably less than 1.5 mEq, more preferably less than 0.3 mEq.
  • The amino sugar herein used includes, for example, meglumine (i.e. N-methyl-D-glucamine), D-glucosamine, D-galactosamine, D-mannosamine, mycosamine, kanosamine, neosamine C, N-methyl-L-glucosamine, mycaminose, muramic acid, and streptamine.
  • Amongst these amino sugars, the preferable amino sugars are meglumine, D-glucosamine, D-galactosamine, D-mannosamine, mycosamine, kanosamine, neosamine C, N-methyl-L-glucosamine, mycaminose, muramic acid, and streptamine; especially meglumine and D-glucosamine are more preferable. The above amino sugars may be used as a single ingredient or a combination consisting of two or more ingredients.
  • The concentration of the amino sugar in the pharmaceutical composition of the invention is, for example, about 0.1% (W/V) to about 15% (W/V), preferably about 0.5% (W/V) to about 10% (W/V), more preferably about 1% (W/V) to about 8% (W/V).
  • The buffer agent herein used includes, for example, an acid which is not in cation form, such as boric acid, phosphoric acid, an amino acid, and an organic acid; preferably boric acid and phosphoric acid are used. The above buffer agents may be used as a single ingredient or a combination consisting of two or more ingredients.
  • The concentration of the buffer agent in the pharmaceutical composition of the invention is, for example, about 0.01% (W/V) to about 4% (W/V), preferably about 0.03% (W/V) to about 3% (W/V), more preferably about 0.05% (W/V) to about 2% (W/V).
  • The pharmaceutical composition of the invention may optionally contain a pH adjuster. The pH adjuster includes, for example, a conventional acid which is in cation-free form, such as hydrochloric acid, lactic acid, acetic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid, and citric acid; preferably hydrochloric acid and citric acid are used. The pH adjusters may be used as a single ingredient or a combination consisting of two or more ingredients.
  • The pharmaceutical composition of the invention may optionally contain an isotonic agent in order to make the pharmaceutical composition isotonic to an aqueous tear. The isotonic agent is preferably a cation-free isotonic agent, which includes a conventional agent for ophthalmic solution such as mannitol, glycerin, polypropylene glycol, polyethylene glycol, maltose, sucrose, sorbitol, and glucose, more preferably a cation-free glycerin and sucrose are used. The isotonic agents may be used as a single ingredient or a combination consisting of two or more ingredients.
  • The pharmaceutical composition of the invention may optionally contain a solubilizing agent. The solubilizing agent includes, for example, a cation-free solubilizing agent. The cation-free solubilizing agent includes, for example, a polymer such as polyvinyl-pyrrolidone, macrogol (polyethylene glycol), polyvinyl alcohol, and hydroxypropylmethylcellulose; a surfactant such as polysorbate, polyoxyethylene hydrogenated castor oil, and polyoxyethylene-polyoxypropylene; a polyhydric alcohol such as polypropylene glycol; an organic acid such as benzoic acid and sorbic acid; an amino acid such as alginic acid, histidine, glycine, and lysine; and a xanthine derivative such as caffeine. The preferable solubilizing agent is polyvinylpyrrolidone, macrogol, polyvinyl alcohol, benzoic acid, sorbic acid, and alginic acid; especially, more preferable solubilizing agent is polyvinylpyrrolidone and macrogol. The solubilizing agents may be used as a single ingredient or a combination consisting of two or more ingredients.
  • The molecular weight of polyvinylpyrrolidone herein used is preferably not more than 200,000, more preferably not more than 40,000. The preferable polyvinyl-pyrrolidone includes, not limited thereto, polyvinyl-pyrrolidone (PVP, BASF, Grade: Kollidon® 25): PVP (K-25), and polyvinylpyrrolidone (PVP, BASF, Grade: Kollidon® 17PF): PVP (K-17PF). The concentration ratio of rebamipide and polyvinylpyrrolidone is preferably 20:1-1:20, more preferably 4:1-1:6.
  • The molecular weight of macrogol herein used is preferably not more than 50,000, more preferably not more than 10,000. The preferable macrogol includes, not limited thereto, macrogol 1500, macrogol 4000, macrogol 6000, and macrogol 20000. The concentration ratio of rebamipide and macrogol is preferably 20:1-1:20, more preferably 4:1-1:6.
  • In case of adding a solubilizing agent to the present composition, the concentration of solubilizing agent is in a range of generally about 0.01 (W/V)-about 15 (W/V) %, preferably about 0.1 (W/V) %-about 10 (W/V) %, and more preferably about 0.5 (W/V) %-about 6 (W/V) %.
  • The pharmaceutical composition of the invention may optionally comprise a conventional preservative such as a quaternary ammonium salt (e.g. benzalkonium chloride, and benzethonium chloride, chlorhexidine gluconate, a paraoxybenzoate (e.g. methyl paraoxybenzoate and propyl paraoxybenzoate), and an alcohol compound (e.g. chlorobutanol and benzyl alcohol); and/or stabilizing agent such as an inorganic-cation-free ascorbic acid and tocopherol.
  • In case that the present pharmaceutical composition is an aqueous liquid preparation, the pH is about 3-about 9, preferably about 7-about 9, and the most preferably 7.7-9.
  • The ratio between (1) rebamipide and (2) an amino sugar comprised in the present composition depends on the type of ingredients used herein and the formulation type of the composition. The amount of (1) rebamipide is, but not limited to, for example, in about 0.01-about 10 parts by weight, preferably about 0.05-about 2 parts by weight, more preferably about 0.1-about 1.5 parts by weight, and the most preferably 0.1-1 part by weight, per one part by weight of (2) an amino sugar.
  • A preferable pharmaceutical composition of the present invention is a pharmaceutical composition comprising (1) rebamipide, (2) meglumine and (3) boric acid, which comprises no inorganic cation. A more preferable pharmaceutical composition is a pharmaceutical composition comprising 0.5% (W/V) to 3% (W/V) rebamipide, 0.5% (W/V) to 10% (W/V) meglumine, and 0.03% (W/V) to 3% (W/V) boric acid, which comprises no inorganic cation. An even more preferable pharmaceutical composition is a pharmaceutical composition comprising 1 (W/V) to 2% (W/V) rebamipide, 1 (W/V) to 8% (W/V) meglumine, 0.05% (W/V) to 2% (W/V) boric acid, and a pH adjuster selected from the group consisting of citric acid and hydrochloric acid, which comprises no inorganic cation.
  • The most preferable pharmaceutical composition is the above-mentioned pharmaceutical composition further comprising polyvinylpyrrolidone as a solubilizing agent. The concentration of the solubilizing agent is preferably 0.5 (W/V) % to 6 (W/V).
    • Effect of the Invention
  • The transparency of the present pharmaceutical composition comprising (1) rebamipide, (2) an amino sugar, and (3) an buffer agent can be enhanced by not containing any inorganic cation. The present pharmaceutical composition is unnecessary to be re-dispersed, additionally it can be formulated into an aqueous preparation which has an enough transparency, and exhibits neutral to weakly acidic pH.
  • The present pharmaceutical composition has an antiseptic effect, thus it is expected to exhibit a preservative effect. Therefore, the present aqueous preparation is not necessary to comprise a conventional preservative (e.g. a quaternary ammonium salt such as benzalkonium chloride and benzethonium chloride; a cationic compound such as chlorhexidine gluconate; a paraoxy benzoate such as methyl paraoxybenzoate and propyl paraoxybenzoate; and an alcohol compound such as chlorobutanol and benzyl alcohol).
  • In addition, the present pharmaceutical composition is so stable, thus it is not necessary to add hereto any stabilizing agent (e.g. an inorganic-cation-free ascorbic acid and tocopherol).
  • The manufacturing process of the present pharmaceutical composition can be carried out at low cost, not via any troublesome process, without using any special dispersing/suspending device, which is an industrially great merit.
  • The present aqueous ophthalmic product can prevent an undesirable blurred vision of an applied patient, thus it is expected to markedly enhance the compliance of a patient suffering from dry eye, and it enables the use of a multi-use vessel equipped with an aseptic filter around the drip opening which is for a preservative-free ophthalmic agent, because it can be pass through an aseptic filter. Therefore, the present invention will provide a great amount of medicinal contribution.
  • In addition, the present pharmaceutical composition has an excellent transparency, thus there is no trouble of making some white spots on the cloths when spilling the composition.
    • BEST MODE FOR CARRYING OUT THE INVENTION
  • The present invention is illustrated in more detail by the following examples, but should not be construed to be limited thereto.
    • Example 1
  • Rebamipide 2 g
    Polyvinylpyrrolidone (K-25) 3 g
    Boric acid 1.5 g
    Meglumine 5.9 g
    Glycerin 0.722 g
    Hydrochloric acid q.s. (to
    pH = 8.3)
    Purified water q.s.
    Total 100 mL
    Note:
    q.s. means quantum sufficiat.
  • To a moderate amount of purified water were added rebamipide, polyvinylpyrrolidone (K-25), boric acid, meglumine, and glycerin while stirring, and the pH of the resulting solution was adjusted with hydrochloric acid. The stirring was done with a low-speed propeller stirrer, without a high-speed stirrer such as a homomixer and a homogenizer. Every ingredient was easily dissolved with the low-speed propeller stirrer. Then, the resulting solution was aseptically filtered through a 0.2 μm filter to provide a pharmaceutical composition. The pharmaceutical composition was a light-yellowish to pale-yellowish transparent solution.
    • Example 2
  • Rebamipide 2 g
    Polyvinylpyrrolidone (K-25) 3 g
    Boric acid 1 g
    Meglumine 4.3 g
    Glycerin 1.185 g
    Hydrochloric acid q.s. (to
    pH = 8.3)
    Purified water q.s.
    Total 100 mL
  • To a moderate amount of purified water were added rebamipide, polyvinylpyrrolidone (K-25), boric acid, meglumine, and glycerin while stirring, and the pH of the resulting solution was adjusted with hydrochloric acid. The stirring was done with a low-speed propeller stirrer, without a high-speed stirrer such as a homomixer and a homogenizer. Every ingredient was easily dissolved with the low-speed propeller stirrer. Then, the resulting solution was aseptically filtered through a 0.2 μm filter to provide a pharmaceutical composition. The pharmaceutical composition was a light-yellowish to pale-yellowish transparent solution.
    • Example 3
  • Rebamipide 2 g
    Polyvinylpyrrolidone (K-25) 1 g
    Boric acid 1.5 g
    Meglumine 6 g
    Glycerin 0.796 g
    Hydrochloric acid q.s. (to
    pH = 8.5)
    Purified water q.s.
    Total 100 mL
  • To a moderate amount of purified water were added rebamipide, polyvinylpyrrolidone (K-25), boric acid, meglumine, and glycerin while stirring, and the pH of the resulting solution was adjusted with hydrochloric acid. The stirring was done with a low-speed propeller stirrer, without a high-speed stirrer such as a homomixer and a homogenizer. Every ingredient was easily dissolved with the low-speed propeller stirrer. Then, the resulting solution was aseptically filtered through a 0.2 μm filter to provide a pharmaceutical composition. The pharmaceutical composition was a colorless to light-yellowish transparent solution.
    • Example 4
  • Rebamipide 2 g
    Polyvinylpyrrolidone (K-25) 6 g
    Boric acid 1.5 g
    Meglumine 5.9 g
    Glycerin 0.398 g
    Hydrochloric acid q.s. (to
    pH = 8.3)
    Purified water q.s.
    Total 100 mL
  • To a moderate amount of purified water were added rebamipide, polyvinylpyrrolidone (K-25), boric acid, meglumine, and glycerin while stirring, and the pH of the resulting solution was adjusted with hydrochloric acid. The stirring was done with a low-speed propeller stirrer, without a high-speed stirrer such as a homomixer and a homogenizer. Every ingredient was easily dissolved with the low-speed propeller stirrer. Then, the resulting solution was aseptically filtered through a 0.2 μm filter to provide a pharmaceutical composition. The pharmaceutical composition was a light-yellowish to pale-yellowish transparent solution.
    • Example 5
  • Rebamipide 1 g
    Polyvinylpyrrolidone (K-25) 3 g
    Boric acid 1.5 g
    Meglumine 4.7 g
    Glycerin 0.991 g
    Hydrochloric acid q.s. (to
    pH = 8.0)
    Purified water q.s.
    Total 100 mL
  • To a moderate amount of purified water were added rebamipide, polyvinylpyrrolidone (K-25), boric acid, meglumine, and glycerin while stirring, and the pH of the resulting solution was adjusted with hydrochloric acid. The stirring was done with a low-speed propeller stirrer, without a high-speed stirrer such as a homomixer and a homogenizer. Every ingredient was easily dissolved with the low-speed propeller stirrer. Then, the resulting solution was aseptically filtered through a 0.2 μm filter to provide a pharmaceutical composition. The pharmaceutical composition was a light-yellowish to pale-yellowish transparent solution.
    • Example 6
  • Rebamipide 1 g
    Polyvinylpyrrolidone (K-25) 3 g
    Boric acid 1 g
    Meglumine 3.4 g
    Glycerin 1.389 g
    Hydrochloric acid q.s. (to
    pH = 8.0)
    Purified water q.s.
    Total 100 mL
  • To a moderate amount of purified water were added rebamipide, polyvinylpyrrolidone (K-25), boric acid, meglumine, and glycerin while stirring, and the pH of the resulting solution was adjusted with hydrochloric acid. The stirring was done with a low-speed propeller stirrer, without a high-speed stirrer such as a homomixer and a homogenizer. Every ingredient was easily dissolved with the low-speed propeller stirrer. Then, the resulting solution was aseptically filtered through a 0.2 μm filter to provide a pharmaceutical composition. The pharmaceutical composition was a light-yellowish to pale-yellowish transparent solution.
    • Example 7
  • Rebamipide 1 g
    Polyvinylpyrrolidone (K-25) 1 g
    Boric acid 1.5 g
    Meglumine 5 g
    Glycerin 1.046 g
    Hydrochloric acid q.s. (to
    pH = 8.2)
    Purified water q.s.
    Total 100 mL
  • To a moderate amount of purified water were added rebamipide, polyvinylpyrrolidone (K-25), boric acid, meglumine, and glycerin while stirring, and the pH of the resulting solution was adjusted with hydrochloric acid. The stirring was done with a low-speed propeller stirrer, without a high-speed stirrer such as a homomixer and a homogenizer. Every ingredient was easily dissolved with the low-speed propeller stirrer. Then, the resulting solution was aseptically filtered through a 0.2 μm filter to provide a pharmaceutical composition. The pharmaceutical composition was a colorless to light-yellowish transparent solution.
    • Example 8
  • Rebamipide 1 g
    Polyvinylpyrrolidone (K-25) 6 g
    Boric acid 1.5 g
    Meglumine 4.7 g
    Glycerin 0.676 g
    Hydrochloric acid q.s. (to
    pH = 8.0)
    Purified water q.s.
    Total 100 mL
  • To a moderate amount of purified water were added rebamipide, polyvinylpyrrolidone (K-25), boric acid, meglumine, and glycerin while stirring, and the pH of the resulting solution was adjusted with hydrochloric acid. The stirring was done with a low-speed propeller stirrer, without a high-speed stirrer such as a homomixer and a homogenizer. Every ingredient was easily dissolved with the low-speed propeller stirrer. Then, the resulting solution was aseptically filtered through a 0.2 μm filter to provide a pharmaceutical composition. The pharmaceutical composition was a light-yellowish to pale-yellowish transparent solution.
    • Example 9
  • A yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 1, using polyvinylpyrrolidone (K-17) in place of polyvinylpyrrolidone (K-25).
    • Example 10
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 2, using polyvinylpyrrolidone (K-17) in place of polyvinylpyrrolidone (K-25).
    • Example 11
  • A colorless to light-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 3, using polyvinylpyrrolidone (K-17) in place of polyvinylpyrrolidone (K-25).
    • Example 12
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 4, using polyvinylpyrrolidone (K-17) in place of polyvinylpyrrolidone (K-25).
    • Example 13
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 5, using polyvinylpyrrolidone (K-17) in place of polyvinylpyrrolidone (K-25).
    • Example 14
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 6, using polyvinylpyrrolidone (K-17) in place of polyvinylpyrrolidone (K-25).
    • Example 15
  • A colorless to light-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 7, using polyvinylpyrrolidone (K-17) in place of polyvinylpyrrolidone (K-25).
    • Example 16
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 8, using polyvinylpyrrolidone (K-17) in place of polyvinylpyrrolidone (K-25).
    • Example 17
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 1, using citric acid in place of hydrochloric acid.
    • Example 18
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 2, using citric acid in place of hydrochloric acid.
    • Example 19
  • A colorless to light-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 3, using citric acid in place of hydrochloric acid.
    • Example 20
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 4, using citric acid in place of hydrochloric acid.
    • Example 21
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 5, using citric acid in place of hydrochloric acid.
    • Example 22
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 6, using citric acid in place of hydrochloric acid.
    • Example 23
  • A colorless to light-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 7, using citric acid in place of hydrochloric acid.
    • Example 24
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 8, using citric acid in place of hydrochloric acid.
    • Example 25
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 1, using sucrose (2.889 g) in place of glycerin (0.722 g).
    • Example 26
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 2, using sucrose (4.741 g) in place of glycerin (1.185 g).
    • Example 27
  • A colorless to light-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 3, using sucrose (3.185 g) in place of glycerin (0.796 g).
    • Example 28
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 4, using sucrose (1.593 g) in place of glycerin (0.398 g).
    • Example 29
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 5, using sucrose (3.963 g) in place of glycerin (0.991 g).
    • Example 30
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 6, using sucrose (5.556 g) in place of glycerin (1.389 g).
    • Example 31
  • A colorless to light-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 7, using sucrose (4.185 g) in place of glycerin (1.046 g).
    • Example 32
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 8, using sucrose (2.704 g) in place of glycerin (0.676 g).
    • Example 33
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 1, using sucrose (2.889 g) in place of glycerin (0.722 g) and using citric acid in place of hydrochloric acid.
    • Example 34
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 5, using sucrose (3.963 g) in place of glycerin (0.991 g) and using citric acid in place of hydrochloric acid.
    • Example 35
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 1, using sucrose (2.889 g) in place of glycerin (0.722 g) and using phosphoric acid in place of hydrochloric acid.
    • Example 36
  • A light-yellowish to pale-yellowish transparent pharmaceutical composition was prepared in a similar manner to Example 5, using sucrose (3.963 g) in place of glycerin (0.991 g) and using phosphoric acid in place of hydrochloric acid.
    • Example 37
  • Rebamipide 2 g
    Boric acid 1.5 g
    Meglumine 6.2 g
    Glycerin 0.861 g
    Hydrochloric acid q.s. (to
    pH = 8.7)
    Purified water q.s.
    Total 100 mL
  • To a moderate amount of purified water were added rebamipide, boric acid, meglumine, and glycerin while stirring, and the pH of the resulting solution was adjusted with hydrochloric acid. The stirring was done with a low-speed propeller stirrer, without a high-speed stirrer such as a homomixer and a homogenizer. Every ingredient was easily dissolved with the low-speed propeller stirrer. Then, the resulting solution was aseptically filtered through a 0.2 μm filter to provide a pharmaceutical composition. The pharmaceutical composition was a colorless transparent solution.
    • Example 38
  • Rebamipide 2 g
    Boric acid 1 g
    Meglumine 4.5 g
    Glycerin 1.259 g
    Hydrochloric acid q.s. (to
    pH = 8.7)
    Purified water q.s.
    Total 100 mL
  • To a moderate amount of purified water were added rebamipide, boric acid, meglumine, and glycerin while stirring, and the pH of the resulting solution was adjusted with hydrochloric acid. The stirring was done with a low-speed propeller stirrer, without a high-speed stirrer such as a homomixer and a homogenizer. Every ingredient was easily dissolved with the low-speed propeller stirrer. Then, the resulting solution was aseptically filtered through a 0.2 μm filter to provide a pharmaceutical composition. The pharmaceutical composition was a colorless transparent solution.
    • Example 39
  • Rebamipide 1 g
    Boric acid 1.5 g
    Meglumine 5.2 g
    Glycerin 1.287 g
    Hydrochloric acid q.s. (to
    pH = 8.4)
    Purified water q.s.
    Total 100 mL
  • To a moderate amount of purified water were added rebamipide, boric acid, meglumine, and glycerin while stirring, and the pH of the resulting solution was adjusted with hydrochloric acid. The stirring was done with a low-speed propeller stirrer, without a high-speed stirrer such as a homomixer and a homogenizer. Every ingredient was easily dissolved with the low-speed propeller stirrer. Then, the resulting solution was aseptically filtered through a 0.2 μm filter to provide a pharmaceutical composition. The pharmaceutical composition was a colorless transparent solution.
    • Example 40
  • Rebamipide 1 g
    Boric acid 1 g
    Meglumine 3.6 g
    Glycerin 1.565 g
    Hydrochloric acid q.s. (to
    pH = 8.0)
    Purified water q.s.
    Total 100 mL
  • To a moderate amount of purified water were added rebamipide, boric acid, meglumine, and glycerin while stirring, and the pH of the resulting solution was adjusted with hydrochloric acid. The stirring was done with a low-speed propeller stirrer, without a high-speed stirrer such as a homomixer and a homogenizer. Every ingredient was easily dissolved with the low-speed propeller stirrer. Then, the resulting solution was aseptically filtered through a 0.2 μm filter to provide a pharmaceutical composition. The pharmaceutical composition was a colorless transparent solution.
    • Example 41
  • A colorless transparent pharmaceutical composition was prepared in a similar manner to Example 37, using citric acid in place of hydrochloric acid.
    • Example 42
  • A colorless transparent pharmaceutical composition was prepared in a similar manner to Example 39, using citric acid in place of hydrochloric acid.
    • Example 43
  • A colorless transparent pharmaceutical composition was prepared in a similar manner to Example 37, using sucrose (3.444 g) in place of glycerin (0.861 g).
    • Example 44
  • A colorless transparent pharmaceutical composition was prepared in a similar manner to Example 39, using sucrose (5.148 g) in place of glycerin (1.287 g).
    • Example 45
  • A colorless transparent pharmaceutical composition was prepared in a similar manner to Example 37, using sucrose (3.444 g) in place of glycerin (0.861 g) and using citric acid in place of hydrochloric acid.
    • Example 46
  • A colorless transparent pharmaceutical composition was prepared in a similar manner to Example 39, using sucrose (5.148 g) in place of glycerin (1.287 g) and using citric acid in place of hydrochloric acid.
    • Example 47
  • A colorless transparent pharmaceutical composition was prepared in a similar manner to Example 37, using sucrose (3.444 g) in place of glycerin (0.861 g) and using phosphoric acid in place of hydrochloric acid.
    • Example 48
  • A colorless transparent pharmaceutical composition was prepared in a similar manner to Example 39, using sucrose (5.148 g) in place of glycerin (1.287 g) and using phosphoric acid in place of hydrochloric acid.
  • The compositions of Examples 4952 and Comparative examples 1-5 shown in the following Table 1 were prepared in the same manner as Example 1, using each ingredient and each amount thereof described in Table 1, each of which was a transparent pharmaceutical composition having a pH range of 7-9. The compositions were stored in a refrigerator for 4 weeks and then each aspect of the compositions was observed and recorded. In the result, a precipitate or gel was formed in the pharmaceutical compositions of Comparative examples 1-5 which contained an inorganic cation. While, in the pharmaceutical compositions of Examples 49-52 which did not contain any inorganic cation, a precipitate or gel was not formed at all.
  • TABLE 1
    Example Comparative Comparative Comparative Comparative Example Comparative Example Example
    49 example 1 example 2 example 3 example 4 50 example 5 51 52
    Rebamipide (g)   2.02   2.02   2.02   2.02   2.02   2.02   2.02   2.02   2.02
    Meglumine (g) 5 5 5 5 5 5 5 5 5
    PVP K25 (g) 4 4 4 4 4 4 4 — —
    Macrogol (g) — — — — — — — — 3
    Boric acid (g) 1 — — — — 1 1 1 1
    Borax 1) (g) —  1.9 — — — — — — —
    Phosphate Na (g) — — 1 — — — — — —
    Citrate Na (g) — — — 1 — — — — —
    Carbonate Na (g) — — — — 1 — — — —
    Citric anhydride q.s. q.s. q.s. q.s. q.s. — q.s. q.s. q.s.
    10% HCl — — — — — q.s. — — —
    Glycerin (g)   0.706   0.706   0.706   0.706   0.706   0.706 —   0.706   0.706
    NaCl (g) — — — — — —   0.25 — —
    Purified water 2) q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s.
    1) 1.9 g of borax: 1 g of sodium tetraborate
    2) “q.s.” of purified water: the total volume the preparation was adjusted to 100 mL with purified water.
  • In order to confirm the good transparency and the good permeability of the present pharmaceutical composition, Example 1, Example 37, Comparative example 6 according to WO 2008/050896, and Comparative example 7 according to WO 2006/052018 were prepared. Shortly after each composition was prepared, each the aspect, the optical transparency at 640 nm, and the filtration performance over a 0.2 μm membrane filter were observed and recorded. After the compositions were stood at room temperature for four weeks, each the aspect was observed and recorded.
  • The results are shown in Table 2. In the present pharmaceutical compositions (Examples 1 and 37), the optical transparency thereof was not interrupted, the filtration performance thereof was good, and the aspect thereof was not changed even after 4 weeks. While, the pharmaceutical composition of Comparative example 6 was milky white, i.e. not transparent, and it was hard to be filtered. The pharmaceutical composition of Comparative example 7 was white, and it could not be filtered since the filter was blocked with its crystal. In addition, the pharmaceutical composition of Comparative example 7 which was stood for 4 weeks had to be vigorously shaken for re-dispersion since the crystal was deposited.
    • Comparative Example 6 Preparation of Suspension Containing 2 W/V % Crystalline Rebamipide
  • To 700 mL of an aqueous sodium hydroxide solution prepared by dissolving 4.4 g of sodium hydroxide in purified water was added 20 g of rebamipide. The mixture was dissolved by heating and then the solution was cooled to 30-40° C. On the other hand, 12 mL of 10 N hydrochloric acid, 68 mL of purified water and 200 mL of aqueous 10 W/V % hydroxypropylmethylcellulose (manufactured by Shin-Etsu Chemical Co., Ltd, TC-5E) were mixed and the solution was cooled in an ice bath. To the solution stirred at 1400 rpm, the above sodium hydroxide solution containing rebamipide was gradually poured under sonication to deposit a crystal of rebamipide. After the crystal was deposited, the stirring speed was picked up to 3000 rpm, and the mixture was stirred for additional 20 minutes. After completing the deposition, the pH of the mixture was adjusted to 6-6.5 with 5 N sodium hydroxide, and the total volume thereof was adjusted to 1 liter with purified water to provide the desired aqueous suspension containing crystalline rebamipide.
    • Comparative Example 7 Preparation of Suspension Containing 2% (W/V) Rebamipide
  • To 80 mL of purified water were added 0.5 g of partially-saponified polyvinyl alcohol (manufactured by KURARAY CI., LTD, Poval 224C), 0.11 g of citric acid, 0.146 g of sodium citrate, 0.715 g of sodium chloride and 0.180 g of potassium chloride, and the mixture was dissolved by heating. After cooling the solution, the solution was filtrated. To the filtrate was added rebamipide, and the resulting mixture was stirred. Then, the total volume thereof was adjusted to 100 mL with purified water to provide the desired aqueous suspension.
  • TABLE 2
    Comparative Comparative
    Composition Example 1 Example 37 example 6 example 7
    Shortly after Aspect transparent transparent milky white white
    preparation transparent
    Optical 100.0 100.0 44.5 0.0
    transparency
    at 640 nm (%)
    Filtration very good very good a little blocked with
    performance bad crystal
    over a 0.2 μm
    membrane
    filter
    After Aspect not changed not changed not changed Crystal was
    4 weeks deposited.
    Re-dispersed
    by
    vigorously
    shaking.
    • Antimicrobial Effectiveness Test (Bacterial Strains)
  • The following strains were used as an inoculum of the test.
  • bacteria: Escherichia Coli NBRC 3972
      • Pseudomonas aeruginosa NBRC 13275
      • Staphylococcus aureus NBRC 13276
        yeast and molds: Candida albicans NBRC 1594
      • Aspergillus niger NBRC 9455
    (Test Samples)
  • Examples 53-58 were prepared in a similar manner to Example 1 using ingredients listed in Table 3.
  • TABLE 3
    The compositions for antimicrobial effectiveness test
    Example Example Example Example Example Example
    53 54 55 56 57 58
    Rebamipide 2 g 2 g 2 g 2 g 2 g 2 g
    PVP (K25) — — 3 g 3 g — —
    PVP (K17) — — — — 3 g 3 g
    Boric acid 1.5 g 2 g 1.5 g 2 g 1.5 g 1.2 g
    Meglumine 6.2 g 7.9 g 5.9 g 7.4 g 5.7 g 4.8 g
    Glycerin 0.972 g 0.616 g 0.844 g 0.5 g 0.819 g 1.05 g
    10% HCl q.s. q.s. q.s. q.s. q.s. q.s.
    (pH) (ca 8.7) (ca 8.7) (ca 8.3) (ca 8.3) (ca 8.3) (ca 8.3)
    Purified water q.s. q.s. q.s. q.s. q.s. q.s.
    Total 100 mL 100 mL 100 mL 100 mL 100 mL 100 mL
    Note)
    PVP means polyvinylpyrrolidone.
    • (Method)
  • Each inoculum was aseptically added to Examples 53-58 at 105-106 cfu/mL, and each composition was uniformly mixed to provide each test sample. These samples were stored at 20-25° C. protected from light. On 0, 14 and 28 days, each 1 mL was sampled from each test sample, and measured as to its viable cell count.
  • The measure of viable cell count of yeast and molds was carried out as follows. Each of the sample solutions was diluted in a tenfold dilutions with SCDLP medium. 1 mL of each grade of the dilutions was plated and 15-20 mL of SCDLP agar medium was added thereto. After cultivating the medium at 30-35° C. for 5 days, the measure of viable cell count was carried out. A plate wherein the viable cell count was not more than 300 was selected and the number of the count was recorded.
  • The measure of viable cell count of fungi was carried out as follows. Each of the sample solutions was diluted in a tenfold dilutions with GPLP medium. 1 mL of each grade of the dilutions was plated and 15-20 mL of GPLP agar medium was added thereto. After cultivating the medium at 20-25° C. for 5 days, the measure of viable cell count was carried out. A plate wherein the viable cell count was not more than 100 was selected and the number of the count was recorded.
  • The viable cell count of each sample solution was provided by multiplying the recorded number by its dilution rate, and additionally the percentage of the viable cell count per the initial viable cell count was calculated.
    • (Determination)
  • For bacteria, the determination of “good” was given; in case that the percentage on 14th day was not more than 0.1%; and the percentage on 28th day was the same level as the 14th day's result or less. The determination of the antimicrobial effectiveness was judged as “conforming” in case that the both were “acceptable”.
  • For yeast and molds, the determination of “good” was given, in case that the percentage was the same level as initial or less. The determination of the antimicrobial effectiveness was judged as “yes” in case that the both results on 14th day and 28th day were “good”.
    • (Result)
  • All Examples 53-58 were judged to have antimicrobial effectiveness.
  • TABLE 4
    The result of antimicrobial effectiveness test
    Results
    After 14 After 28 Antimicrobial
    Bacterial strain days days effectiveness
    Example 53 E. Coli acceptable acceptable conforming
    P. aeruginosa acceptable acceptable conforming
    S. aureus acceptable acceptable conforming
    C. albicans acceptable acceptable conforming
    A. niger acceptable acceptable conforming
    Example 54 E. Coli acceptable acceptable conforming
    P. aeruginosa acceptable acceptable conforming
    S. aureus acceptable acceptable conforming
    C. albicans acceptable acceptable conforming
    A. niger acceptable acceptable conforming
    Example 55 E. Coli acceptable acceptable conforming
    P. aeruginosa acceptable acceptable conforming
    S. aureus acceptable acceptable conforming
    C. albicans acceptable acceptable conforming
    A. niger acceptable acceptable conforming
    Example E. Coli acceptable acceptable conforming
    56 P. aeruginosa acceptable acceptable conforming
    S. aureus acceptable acceptable conforming
    C. albicans acceptable acceptable conforming
    A. niger acceptable acceptable conforming
    Example E. Coli acceptable acceptable conforming
    57 P. aeruginosa acceptable acceptable conforming
    S. aureus acceptable acceptable conforming
    C. albicans acceptable acceptable conforming
    A. niger acceptable acceptable conforming
    Example E. Coli acceptable acceptable conforming
    58 P. aeruginosa acceptable acceptable conforming
    S. aureus acceptable acceptable conforming
    C. albicans acceptable acceptable conforming
    A. niger acceptable acceptable conforming

Claims (9)

1. A pharmaceutical composition comprising (1) rebamipide, (2) an amino sugar, and (3) a buffer agent, which has no inorganic cation.
2. The pharmaceutical composition of claim 1 wherein the amino sugar is at least one selected from the group consisting of D-glucosamine and meglumine.
3. The pharmaceutical composition of claim 2 wherein the buffer agent is at least one selected from the group consisting of boric acid, phosphoric acid and an amino acid.
4. The pharmaceutical composition of claim 3, further comprising a pH adjuster.
5. The pharmaceutical composition of claim 4, further comprising a solubilizing agent.
6. The pharmaceutical composition of claim 5 wherein the solubilizing agent is at least one selected from the group consisting of polyvinylpyrrolidone and macrogol.
7. The pharmaceutical composition of any one of claims 1 to 6 wherein the pharmaceutical composition is an ophthalmic pharmaceutical composition.
8. (canceled)
9. A method for treating dry eye comprising topically administering an effective amount of the pharmaceutical composition of any one of claims 1 to 6 to a patient's eyes in need thereof.
US12/999,967 2008-06-19 2009-06-18 Pharmaceutical composition comprising rebamipide Abandoned US20110124682A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008160084 2008-06-19
JP2008-160084 2008-06-19
PCT/JP2009/061553 WO2009154304A2 (en) 2008-06-19 2009-06-18 A pharmaceutical composition

Publications (1)

Publication Number Publication Date
US20110124682A1 true US20110124682A1 (en) 2011-05-26

Family

ID=41334556

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/999,967 Abandoned US20110124682A1 (en) 2008-06-19 2009-06-18 Pharmaceutical composition comprising rebamipide

Country Status (26)

Country Link
US (1) US20110124682A1 (en)
EP (1) EP2285413B1 (en)
JP (1) JP5441934B2 (en)
KR (1) KR20110027786A (en)
CN (1) CN102099056B (en)
AR (1) AR072212A1 (en)
AU (1) AU2009261101B2 (en)
BR (1) BRPI0915427A2 (en)
CA (1) CA2725487A1 (en)
CO (1) CO6280502A2 (en)
CY (1) CY1113214T1 (en)
DK (1) DK2285413T3 (en)
ES (1) ES2389583T3 (en)
HR (1) HRP20120644T1 (en)
IL (1) IL209329A (en)
MX (1) MX2010013733A (en)
MY (1) MY150558A (en)
NZ (1) NZ589517A (en)
PL (1) PL2285413T3 (en)
PT (1) PT2285413E (en)
RU (1) RU2538694C2 (en)
SI (1) SI2285413T1 (en)
TW (1) TWI495634B (en)
UA (1) UA100164C2 (en)
WO (1) WO2009154304A2 (en)
ZA (1) ZA201008584B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017057973A1 (en) * 2015-10-01 2017-04-06 Samjin Pharmaceutical Co., Ltd. Novel ophthalmic composition comprising rebamipide and method for preparing the same
KR20180121593A (en) 2016-03-14 2018-11-07 산텐 세이야꾸 가부시키가이샤 Preservatives comprising meglumine or salts thereof
US11712414B2 (en) 2013-04-18 2023-08-01 Samjin Pharmaceutical Co., Ltd. Oral pharmaceutical composition for preventing or treating dry eye syndrome comprising rebamipide or a prodrug thereof

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201322982A (en) 2011-11-01 2013-06-16 Otsuka Pharma Co Ltd An agent for treating anterior eye diseases, the agent comprising rebamipide and a tear retention agent
TW201417814A (en) * 2012-09-28 2014-05-16 Otsuka Pharma Co Ltd Pharmaceutical composition comprising rebamipide
WO2015034008A1 (en) * 2013-09-05 2015-03-12 大塚製薬株式会社 Use of rebamipide for local hemostasis
JP6854587B2 (en) * 2015-04-17 2021-04-07 ロート製薬株式会社 Pharmaceutical product
KR102307958B1 (en) 2015-10-01 2021-10-05 삼진제약주식회사 Novel opthalmic composition comprising rebamipide and method for preparing the same
CN106491530B (en) * 2016-12-13 2019-11-29 湖北远大天天明制药有限公司 A kind of medical composite for eye
KR101840256B1 (en) * 2017-09-21 2018-03-21 대우제약 주식회사 A water-soluble eye drop composition for the treatment of dry eye syndrome containing rebamipide and its solubilization and stabilization method
KR101923519B1 (en) 2018-06-26 2019-02-27 대우제약 주식회사 A water-soluble, multi-use eyedrops composition for the treatment of dry eye syndrome containing rebamipide and a method for solubilization and stabilization thereof
KR20200019451A (en) 2018-08-14 2020-02-24 대우제약 주식회사 A water-soluble, multi-use eyedrops composition for the treatment of dry eye syndrome containing rebamipide and a method for solubilization and stabilization thereof
JP6744952B2 (en) * 2019-05-28 2020-08-19 ロート製薬株式会社 Ophthalmic composition
KR102615076B1 (en) 2021-07-14 2023-12-19 대우제약 주식회사 Method for preparing stable rebamipide eye drop on large scale
KR102659338B1 (en) 2023-05-18 2024-04-19 국제약품 주식회사 A pharmaceutical composition for treating dry eye syndrome

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732611B2 (en) * 2004-01-21 2010-06-08 Otsuka Pharmaceutical Co., Ltd. Amine salt of carbostyril derivative

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3093661B2 (en) * 1995-10-12 2000-10-03 大塚製薬株式会社 Eye disease treatment
AR004214A1 (en) * 1995-10-12 1998-11-04 Otsuka Pharma Co Ltd A PREPARATION OF OPHTHALMIC DROPS FOR THE CURE OF OPHTHALMIC DISEASES
EP1243271A1 (en) * 1999-11-11 2002-09-25 Takeda Chemical Industries, Ltd. Nasal drops containing fused pyridazine derivatives
TWI363626B (en) * 2004-11-15 2012-05-11 Otsuka Pharma Co Ltd Aqueous ophthalmic suspension of crystalline rebamipide
TWI415629B (en) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd Aqueous pharmaceutical suspensions containing rebamipide and manufacturing process thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732611B2 (en) * 2004-01-21 2010-06-08 Otsuka Pharmaceutical Co., Ltd. Amine salt of carbostyril derivative

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11712414B2 (en) 2013-04-18 2023-08-01 Samjin Pharmaceutical Co., Ltd. Oral pharmaceutical composition for preventing or treating dry eye syndrome comprising rebamipide or a prodrug thereof
WO2017057973A1 (en) * 2015-10-01 2017-04-06 Samjin Pharmaceutical Co., Ltd. Novel ophthalmic composition comprising rebamipide and method for preparing the same
US20180264120A1 (en) * 2015-10-01 2018-09-20 Samjin Pharmaceutical Co., Ltd. Novel ophthalmic composition comprising rebamipide and method for preparing the same
RU2706353C1 (en) * 2015-10-01 2019-11-18 Самдзин Фармасьютикал Ко.,Лтд. Novel ophthalmic composition containing rebamipide, and method for production thereof
US10918725B2 (en) * 2015-10-01 2021-02-16 Samjin Pharmaceutical Co., Ltd. Ophthalmic composition comprising rebamipide and method for preparing the same
KR20180121593A (en) 2016-03-14 2018-11-07 산텐 세이야꾸 가부시키가이샤 Preservatives comprising meglumine or salts thereof
US11324829B2 (en) 2016-03-14 2022-05-10 Santen Pharmaceutical Co., Ltd. Antiseptic agent comprising meglumine or salt thereof

Also Published As

Publication number Publication date
AU2009261101B2 (en) 2013-11-07
HRP20120644T1 (en) 2012-08-31
CN102099056B (en) 2014-10-01
BRPI0915427A2 (en) 2015-11-03
KR20110027786A (en) 2011-03-16
SI2285413T1 (en) 2012-09-28
PL2285413T3 (en) 2013-01-31
HK1149496A1 (en) 2011-10-07
IL209329A (en) 2014-09-30
UA100164C2 (en) 2012-11-26
TW201006800A (en) 2010-02-16
ES2389583T3 (en) 2012-10-29
WO2009154304A3 (en) 2010-12-02
MY150558A (en) 2014-01-30
ZA201008584B (en) 2012-01-25
RU2011101713A (en) 2012-07-27
TWI495634B (en) 2015-08-11
WO2009154304A2 (en) 2009-12-23
EP2285413B1 (en) 2012-08-08
CN102099056A (en) 2011-06-15
EP2285413A2 (en) 2011-02-23
DK2285413T3 (en) 2012-08-27
AU2009261101A1 (en) 2009-12-23
CY1113214T1 (en) 2016-04-13
IL209329A0 (en) 2011-01-31
AR072212A1 (en) 2010-08-11
MX2010013733A (en) 2011-01-21
RU2538694C2 (en) 2015-01-10
CA2725487A1 (en) 2009-12-23
NZ589517A (en) 2012-09-28
PT2285413E (en) 2012-09-07
JP5441934B2 (en) 2014-03-12
CO6280502A2 (en) 2011-05-20
JP2011524854A (en) 2011-09-08

Similar Documents

Publication Publication Date Title
US20110124682A1 (en) Pharmaceutical composition comprising rebamipide
AU761040B2 (en) Aqueous liquid preparations
WO2011013794A1 (en) Water-based composition for eye drop
EP0976407A1 (en) Antiseptic composition
AU2013320866A1 (en) Pharmaceutical composition comprising rebamipide
AU2023219973A1 (en) Antimicrobial compositions containing polyquaternium
JP3876232B2 (en) Ophthalmic preparations, eye drops, artificial tears, contact lens care products, eye washes, and eye ointments
TW202513068A (en) Ophthalmic pharmaceutical composition with improved preservative effectiveness or light stability
HK1149496B (en) A pharmaceutical composition
JP2005247795A (en) Stable eye drops
JP2004339104A (en) Method for solution stabilization
MXPA00003859A (en) Aqueous liquid preparations
JP2002265364A (en) Liquid containing sodium cromoglycate

Legal Events

Date Code Title Description
AS Assignment

Owner name: OTSUKA PHARMACEUTICAL CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUMIDA, SHUN-ICHIRO;ISHIKAWA, SHINICHI;SIGNING DATES FROM 20101005 TO 20101008;REEL/FRAME:025539/0537

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE